Features of Ursodeoxycholic Acid Use in Various Pathologies of Hepatobiliary Tract and Other Organs and Systems

Yu.M. Stepanov, S.V. Kosynska

Abstract


The article describes the rationale and features of ursodeoxycholic acid (UDCA) application in a wide range of hepatobiliary and extrahepatic pathology. The literature data and own observations of UDCA efficacy in many diseases are provided. The prospects for UDCA use are
determined.


References


Чекман И.С. Современные аспекты метаболической коррекции / И.С. Чекман, В.С. Сухоруков, И.В. Леонтьева, С.О. Ключников // Здоров’я України. — 2007. — № 7. — С. 12.

High-performance liquid chromatographic determination ofursodeoxycholic acidafter solid phase extraction ofbloodserum and detection-oriented derivatization / Nobilis M., Pour M., Kunes J. [et al.] // J. Pharm. Biomed. Anal. — 2001. — Vol. 24, № 5–6. — Р. 937-946.

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C / M. Omata, H. Yoshida, J. Toyota [et al.] // Gut. — 2007. — Vol. 56, № 12. — P. 1747-1753.

Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE / J.M. Lee, G.T. Gang, D.K. Kim [et al.] // J. Biol. Chem. — 2014. — Vol. 289, № 2. — Р. 1079-1091.

Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients / S. Carotti [et al.] // Neurogastroenterol Motil. — 2010. — Vol. 22, № 8. — Р. 866-873

Portincasa P. Therapy of gallstone disease: What it was, what it is, what it will be / P. Portincasa, A.D. Ciaula, L. Bonfrate, D.Q. Wang // World J. Gastrointest. Pharmacol. Ther. — 2012. — Vol. 3, № 2. — Р. 7-20.

Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed / M.P. Guarino, S. Cocca, A. Altomare [et al.] // World J. Gastroenterol. — 2013. — Vol. 19, № 31. — Р. 5029-5034.

Parés A. Old and novel therapies for primary biliary cirrhosis / A. Parés // Semin. Liver Dis. — 2014 Aug. — 34(3). — 341-51.

Abhyankar A. Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient / Abhyankar A., Tapper E., Bonder A. // Pharmaceuticals (Basel). — 2013. — Vol. 7(1). — P. 18-28.

Ursodeoxycholic acid for primary biliary cirrhosis / Rudic J.S. et al. // Cochrane Database Syst Rev. — 2012 Dec 12. — 12. — CD000551.

Lammers W.J. Predicting outcome in primary biliary cirrhosis / Lammers W.J., Kowdley K.V., van Buuren H.R. // Ann. Hepatol. — 2014. — Vol. 13, № 4. — P. 316-326.

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response toursodeoxycholic acid / E.M. Kuiper [et al.] // Gastroenterology. — 2009. — Vol. 136(4). — P. 1281-1287.

Biochemical response toursodeoxycholic acidpredicts survival in a North American cohort of primary biliary cirrhosis patients / С. Lammert [et al.] // J. Gastroenterol. — 2014. — Vol. 49(10). — P. 1414-1420.

Poupon R. Evidence-basedtreatmentofprimary biliary cirrhosis // Dig. Dis. — 2014. — Vol. 32(5). — P. 626-630.

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study / V. Papastergiou [et al.] // Aliment. Pharmacol. Ther. — 2013. — Vol. 38(11–12). — P. 1354-1364.

Al-Harthy N., Kumagi T. Natural history and management of primary biliary cirrhosis // Hepat. Med. — 2012. — Vol. 4. — P. 61-71.

Effect of post-livertransplantation administration ofursodeoxycholic acidon serumlivertests and biliary complications: a randomized clinical trial / S.Y. Wang [et al.] // Zhonghua Gan. Zang. Bing. Za Zhi. — 2014 — Vol. 22, № 7. — Р. 529-535.

Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis C virus infection / S. Nojiri [et al.] // Hepatol. Res. — 2009. — Vol. 39(1). — P. 21-30.

Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C / R.E. Poupon [et al.] // Scand. J. Gastroenterol. — 2000. — 35. — P. 642-649.

Poupon R. Ursodeoxycholic acid in chronic hepatitis C / R. Poupon, L. Serfaty // Gut. — 2007. — Vol. 56, № 12. — P. 1652-1653.

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C / M. Omata [et al.] // Gut. — 2007. — Vol. 56, № 12. — P. 1747-1753.

A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients / S. Sato [et al.] // World J. Gastroenterol. — 2009 — Vol. 15, № 22. — P. 2782-2786.

Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis / K. Tarao [et al.] // Cancer Epidemiol. Biomarkers Prev. — 2005. — Vol. 14, № 1. — Р. 164-169.

Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids / M. Casal Moura [et al.] // World J. Hepatol. — 2014. — Vol. 6, № 6. — Р. 410-418.

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis / C.K. Triantos, N.M. Koukias, V.N. Nikolopoulou, A.K. Burroughs // Aliment. Pharmacol. Ther. — 2011. — Vol. 34, № 8. — Р. 901-910.

High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis / Keith D. Lindor, Kris V. Kowdley, Velimir A.C. Luketic [et al.] // Hepatology. — 2009 — Vol. 50, № 3. — P. 808-814

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis / V. Ratziu, V. de Ledinghen, F. Oberti [et al.] // Journal of hepatology. — 2011. — Vol. 54. — P. 1011-1019.

Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice / Tsuchida T., Shiraishi M., Ohta T., Sakai K., Ishii S. // Metabolism: clinical and experimental. — 2012. — Vol. 61. — P. 944-953.

Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease / Pathil A., Mueller J., Warth A., Chamulitrat W., Stremmel W. // Hepatology. — 2012. — Vol. 55, № 5. — Р. 1369-1378.

Mahmoud Ursodeoxycholic Acid Ameliorates Fructose-Induced Metabolic Syndrome in Rats / Amr. A.A. Mahmoud, Shimaa M. Elshazly // PLoS One. — 2014. — Vol. 9, № 9. — e106993.

A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice / G. Pelletier, D. Roulot, T. Davion [et al.] // Hepatology. — 2003. — Vol. 37, № 4. — Р. 887-892.

Bettini R. Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy / R. Bettini, M. Gorini // Clin. Ter. — 2002. — Vol. 153, № 5. — Р. 305-307.

Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial / S.H. Lee, G.J. Cheon, H.S. Kim [et al.] // Korean J. Gastroenterol. — 2014. — Vol. 64, № 1. — Р. 31-39.

Ursodeoxycholic acid induction of hepatocellular carcinoma cell apoptosis in vitro / Zhu L., Shan L.J., Liu Y.J. et al. // J. Dig. Dis. — 2014. — Sep 12. doi: 10.1111/1751-2980.12191.

In Barrett’s esophagus patients and Barrett’s cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids / S. Peng, X. Huo, D. Rezaei [et al.] // Am. J. Physiol. Gastrointest. Liver. Physiol. — 2014. — Vol. 307, № 2. — Р. G129-139.

Grand’Maison S. The effects of ursodeoxycholic Acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studie / Grand’Maison S., Durand M., Mahone M. // J. Obstet. Gynaecol. Can. — 2014. — Vol. 36, № 7. — Р. 632-641.

Применение урсодезоксихолевой кислоты при внутрипеченочном холестазе беременных / Степанов Ю.М., Ягмур В.Б., Ягмур С.С., Мельниченко Л.Я. // Гастроэнтерология. — 2012. — Вып. 46. — С. 394-403.

Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial / S. Haehling, J.C. Schefold, E.A. Jankowska [et al.] // Am. Coll. Cardiol. — 2012. — Vol. 59, № 6. — Р. 585-592.

Ursodeoxycholic Acid ameliorates pain severity and cartilage degeneration in monosodium iodoacetate-induced osteoarthritis in rats / S.J. Moon, J.H. Jeong, J.Y. Jhun [et al.] // Immune Netw. — 2014. — Vol. 14, № 1. — Р. 45-53.

Ursodeoxycholic acid increases differentiation and mineralization and neutralized the damaging effects of bilirubin on osteoblastic cells / M. Dubreuil, S. Ruiz-Gaspa, P. Peris [et al.] // Liver international. — 2013. — Vol. 33, № 7. —

P. 1029-1038.




DOI: https://doi.org/10.22141/2308-2097.4.54.2014.82088

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru